Should temozolomide be used on the basis of O6-methylguanine DNA methyltransferase status in patients with advanced neuroendocrine tumors? A systematic review and Meta-analysis

Neuroendocrine tumors (NETs) are rare[1] and heterogeneous malignancies that are classified according to their site of origin, morphology, Ki-67 proliferation index, and mitotic count. An updated classification of the World Health Organization (WHO) of digestive neuroendocrine neoplasms (NENs) has been recently published and divides the NENs in neuroendocrine tumors (NET, grade [G]1, G2, G3), neuroendocrine carcinomas (NEC) and mixed non-neuroendocrine and endocrine malignancies (MiNEN)[2].

Source: Cancer Treatment Reviews - July 21, 2021 Category: Cancer & Oncology Authors: P. Trillo Aliaga, F. Spada, G. Peveri, V. Bagnardi, C. Fumagalli, A. Laffi, M. Rubino, L. Gervaso, E. Guerini Rocco, E. Pisa, G. Curigliano, N. Fazio Source Type: research